Latest news with #Divis
Business Standard
24-05-2025
- Business
- Business Standard
Divis Lab inks long-term global pharma deal
Divis Laboratories has announced the signing of a long-term manufacturing and supply agreement with a global pharmaceutical company. As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term. To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer. Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space. The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Business Standard
24-04-2025
- Business
- Business Standard
Divis Lab spurts as broker maintains buy call
Divis Laboratories surged 5.35% to Rs 6234.50 after a leading foreign brokerage maintained its 'Buy' rating on the stock, setting a price target of Rs 7,050 per share. In its latest note, the broker highlighted Divis strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of OrforglipronEli Lillys promising oral GLP-1 candidateto Divis development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030. Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities. Divis Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.
